Drug profile · INN
pridopidine
NURZIGMA
pridopidine (NURZIGMA) is a dopamine d2 receptor modulator.
EMA: application withdrawn Nervous system (N07) N07
Patents linked 5
Pipeline programs 1
News articles 0
Drug details — pridopidine
- Class
- Nervous system (N07)
- Route
- —
- Patents
- 5
- Programs
- 1
- Data quality
- 0.83
Quick answer
pridopidine (NURZIGMA) is a dopamine d2 receptor modulator.
Key facts
INN pridopidine
Brand NURZIGMA
Mechanism Dopamine D2 receptor modulator
Target D(2) dopamine receptor
Therapeutic class Nervous system (N07)
ATC code N07
Mechanism of action
Dopamine D2 receptor modulator
Primary target: D(2) dopamine receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | application withdrawn | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 11471449
Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
granted -
US 10603311
Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
granted -
US 10130621
Analogs of pridopidine, their preparation and use
granted -
US 9814706
Hydrobromide salt of pridopidine
granted -
US 9796673
L-tartrate salt of pridopidine
granted
Frequently asked questions
What is pridopidine?
pridopidine (NURZIGMA) is a dopamine d2 receptor modulator.
What is the brand name for pridopidine?
NURZIGMA is a marketed brand name for pridopidine. Check FDA Drugs@FDA for the current US label holder and prescribing information.